Bluejay Diagnostics (BJDX) Cash from Financing Activities (2020 - 2026)

Bluejay Diagnostics has disclosed Cash from Financing Activities across 6 years of filings, most recently posting $124096.0 for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $124096.0, up 12698.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.2 million (down 2.92% YoY), and the FY2025 annual result was $7.1 million, down 30.63% from the prior year.
• Cash from Financing Activities came in at $124096.0 for Q1 2026 at Bluejay Diagnostics, down from $3.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $7.6 million in Q2 2024 to a low of -$147861.0 in Q3 2024.
• The 4-year median for Cash from Financing Activities is -$985.0 (2025), against an average of $1.4 million.
• Peak annual rise in Cash from Financing Activities reached 283122.25% in 2024, while the deepest fall reached 112.57% in 2024.
• Bluejay Diagnostics' Cash from Financing Activities stood at -$3050.0 in 2023, then surged by 56.52% to -$1326.0 in 2024, then jumped by 279980.24% to $3.7 million in 2025, then plunged by 96.66% to $124096.0 in 2026.
• The last three Cash from Financing Activities figures came in at $124096.0 (Q1 2026), $3.7 million (Q4 2025), and -$1015.0 (Q3 2025), per Business Quant data.